{"id":"W4400408647","doi":"10.1016/j.jhepr.2024.101168","title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","year":2024,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Dalhousie University; University of British Columbia; University of Calgary; University of Ottawa; Western University; University of Toronto; Université de Sherbrooke; Queen's University; Toronto General Hospital; University Health Network; Université de Montréal; University of Saskatchewan; St. Michael's Hospital","funders":"Allergan; Grifols; Ipsen; Novo Nordisk; Swedish Orphan Biovitrum; European Association for the Study of the Liver; Vir Biotechnology; Intercept Pharmaceuticals; Pfizer; Incyte; Bristol-Myers Squibb; Dr. Falk Pharma; CSL Behring; Ultragenyx Pharmaceutical; Canadian Liver Foundation; Celgene; PSC Partners Seeking a Cure; Gilead Sciences; American Association for the Study of Liver Diseases; Kowa Company; Sanofi; Genesis Pharma; LifeArc; Falk Foundation","keywords":"Ursodeoxycholic acid; Medicine; Internal medicine; Liver transplantation; Primary biliary cirrhosis; Gastroenterology; Alkaline phosphatase; Liver disease; Cohort; Bilirubin; Transplantation; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009212032,0.0001474027,0.0002740891,0.0002885022,0.0003797687,0.0005703897,0.0002698862,0.0003250954,0.001176858],"category_scores_gemma":[0.003662977,0.000176879,0.0004656614,0.0004560791,0.0002777798,0.0002534844,0.000419297,0.000568002,0.0001003195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008391496,"about_ca_system_score_gemma":0.0009796564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0162459,"about_ca_topic_score_gemma":0.02269308,"domain_scores_codex":[0.9995926,0.0001399095,0.00004163981,0.00007356599,0.00006772952,0.00008468913],"domain_scores_gemma":[0.9977646,0.0005219485,0.001107906,0.0001055301,0.0001432513,0.0003567544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001562397,0.00002258258,0.9985536,0.000006182589,0.00002397355,0.00002901094,0.00002717135,0.0001407591,0.00004502335,0.00000921872,0.00004751801,0.0009388492],"study_design_scores_gemma":[0.00001258793,0.0001166094,0.9984308,0.00001143436,0.00004149637,0.0001889812,0.00007932885,0.0009422866,0.00004797435,0.00005238788,0.00007244034,0.000003562777],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994524,0.0001837713,0.00005056681,0.00005689409,0.000002782318,0.000003544241,0.00006720417,0.000002276514,0.0001806026],"genre_scores_gemma":[0.9997701,0.00005267874,0.00003182246,0.00001364463,0.000002701539,0.000001731457,0.00009695195,6.234035e-7,0.00002973773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0162459,"threshold_uncertainty_score":0.03230268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00515738763793972,"score_gpt":0.230152378719982,"score_spread":0.2249949910820423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}